

### **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of the Claims**

- 1-55. Canceled
56. (New) A method for treating Hepatitis B virus ("HBV") infection in an HBV-infected human subject comprising administering to the subject a small organic molecule that decreases the activity of a Src kinase family member.
57. (New) A method for inhibiting Hepatitis B virus ("HBV") infection in a human subject comprising administering to the subject a small organic molecule that decreases the activity of a Src kinase family member.
58. (New) A method for inhibiting Hepatitis B virus ("HBV") replication in an HBV-infected human subject comprising administering to the subject a small organic molecule that decreases the activity of a Src kinase family member.
59. (New) The method of claim 56, 57, or 58, further comprising administering to the subject an antiviral agent selected from the group consisting of an interferon, an interleukin, an immune-active peptide, a nucleoside analog, or a corticosteroid.
60. (New) The method of claim 59, wherein the interferon is interferon alpha or interferon delta.
61. (New) The method of claim 59, wherein the interleukin is interleukin-1 or interleukin-2.
62. (New) The method of claim 59, wherein the immune-active peptide is thymosin-alpha.

63. (New) The method of claim 59, wherein the nucleoside analog is vidarabine, fialuridine, lamivuridine, famciclovir, or ribavarin.
64. (New) The method of claim 59, wherein the corticosteroid is prednisone or azathioprine.
65. (New) The method of claim 56, 57, or 58, wherein the small molecule is selected from the group consisting of a tryphostin inhibitor, a pyrazolopyrimidine, a benzylidenemalononitrile, and an angelmicin.
66. (New) The method of claim 65, wherein the small molecule is a pharmaceutically acceptable salt of a tryphostin inhibitor, a pyrazolopyrimidine, a benzylidenemalononitrile, or an angelmicin.
67. (New) The method of claim 56, 57, or 58, wherein the Src kinase family member is a c-Src, a Fyn, a Yes, or a Lyn tyrosine kinase.
68. (New) The method of claim 56, 57, or 58, wherein the Src kinase family member is a homolog or analog of c-Src.